trichostatin A
Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.
Cross Reference
Introduction
To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with trichostatin A?
trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with trichostatin A
PubChem Associated disorders and diseases
What pathways are associated with trichostatin A
Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Related references are published most in these journals:
| Pathway name | Related literatures |
|---|
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with trichostatin A?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with trichostatin A?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with trichostatin A?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with trichostatin A?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with trichostatin A?
Mouse Model
Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).
Xenograft Model
Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).
Cancer Model
Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with trichostatin A
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Humphreys KJ et al. | Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. | 2013 | Mol. Carcinog. | pmid:22308110 |
| Wang X et al. | Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. | 2013 | Mol. Carcinog. | pmid:22121107 |
| Xiong H et al. | Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. | 2012 | Mol. Carcinog. | pmid:21520296 |
| Glaser KB et al. | Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. | 2003 | Mol. Cancer Ther. | pmid:12589032 |
| Rahman R et al. | Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells. | 2010 | Mol. Cancer Ther. | pmid:20643785 |
| Dowdy SC et al. | Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. | 2006 | Mol. Cancer Ther. | pmid:17121923 |
| Saunders LR and Verdin E | Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors. | 2006 | Mol. Cancer Ther. | pmid:17121924 |
| Kim J et al. | PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. | 2010 | Mol. Cancer Ther. | pmid:20571067 |
| Strait KA et al. | Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. | 2002 | Mol. Cancer Ther. | pmid:12479699 |
| Blagosklonny MV et al. | Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. | 2002 | Mol. Cancer Ther. | pmid:12481415 |
| Alao JP et al. | Inhibition of type I histone deacetylase increases resistance of checkpoint-deficient cells to genotoxic agents through mitotic delay. | 2009 | Mol. Cancer Ther. | pmid:19723888 |
| Chung YL et al. | Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. | 2004 | Mol. Cancer Ther. | pmid:15026552 |
| Francia G et al. | Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. | 2005 | Mol. Cancer Ther. | pmid:16227397 |
| Sonnemann J et al. | Serine proteases in histone deacetylase inhibitor-induced apoptosis. | 2010 | Mol. Cancer Ther. | pmid:20682651 |
| Moiseeva EP et al. | Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. | 2007 | Mol. Cancer Ther. | pmid:18025290 |
| GarcÃa-Morales P et al. | Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. | 2005 | Mol. Cancer Ther. | pmid:16093438 |
| Nome RV et al. | Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. | 2005 | Mol. Cancer Ther. | pmid:16093439 |
| Danam RP et al. | Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. | 2005 | Mol. Cancer Ther. | pmid:15657354 |
| Lee JH et al. | Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. | 2006 | Mol. Cancer Ther. | pmid:17172411 |
| Scott GK et al. | Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. | 2002 | Mol. Cancer Ther. | pmid:12477051 |
| De los Santos M et al. | Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. | 2007 | Mol. Cancer Ther. | pmid:17431121 |
| Muscolini M et al. | Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. | 2008 | Mol. Cancer Ther. | pmid:18566213 |
| Ma X et al. | Identification of LIV1, a putative zinc transporter gene responsible for HDACi-induced apoptosis, using a functional gene screen approach. | 2009 | Mol. Cancer Ther. | pmid:19887557 |
| Miyanaga A et al. | Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. | 2008 | Mol. Cancer Ther. | pmid:18606719 |
| Sun F et al. | Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. | 2009 | Mol. Cancer Ther. | pmid:19934278 |
| Roy S et al. | Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells. | 2008 | Mol. Cancer Ther. | pmid:18645003 |
| Strait KA et al. | Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. | 2005 | Mol. Cancer Ther. | pmid:15827334 |
| Ostapkowicz A et al. | Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor. | 2006 | Mol. Cancer Ther. | pmid:16505096 |
| Hellebrekers DM et al. | Angiostatic activity of DNA methyltransferase inhibitors. | 2006 | Mol. Cancer Ther. | pmid:16505122 |
| Jeon HW and Lee YM | Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. | 2010 | Mol. Cancer Ther. | pmid:20442303 |
| Rokhlin OW et al. | Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. | 2006 | Mol. Cancer Res. | pmid:16513842 |
| Gaymes TJ et al. | Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? | 2006 | Mol. Cancer Res. | pmid:16877702 |
| Wischnewski F et al. | Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. | 2006 | Mol. Cancer Res. | pmid:16687489 |
| Link PA et al. | Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. | 2009 | Mol. Cancer Res. | pmid:19531572 |
| Fan T et al. | EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. | 2011 | Mol. Cancer Res. | pmid:21383005 |
| Pan J et al. | TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells. | 2008 | Mol. Cancer Res. | pmid:18505930 |
| Kim M et al. | Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion. | 2008 | Mol. Cancer Res. | pmid:18314483 |
| Ko JM et al. | Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma. | 2008 | Mol. Cancer Res. | pmid:18403638 |
| Liu PY et al. | Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells. | 2008 | Mol. Cancer Res. | pmid:18644983 |
| Hu J and Colburn NH | Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. | 2005 | Mol. Cancer Res. | pmid:15755876 |
| Alimirah F et al. | IFI16 in human prostate cancer. | 2007 | Mol. Cancer Res. | pmid:17339605 |
| Lee JH et al. | Notch signal activates hypoxia pathway through HES1-dependent SRC/signal transducers and activators of transcription 3 pathway. | 2009 | Mol. Cancer Res. | pmid:19808903 |
| Alao JP et al. | Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. | 2006 | Mol. Cancer | pmid:17018141 |
| Arapshian A et al. | Epigenetic CRBP downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer. | 2004 | Mol. Cancer | pmid:15113415 |
| Liu TY et al. | EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. | 2010 | Mol. Cancer | pmid:20144199 |
| Hudson RS et al. | Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. | 2013 | Mol. Cancer | pmid:23409773 |
| Das PM et al. | Methylation mediated silencing of TMS1/ASC gene in prostate cancer. | 2006 | Mol. Cancer | pmid:16848908 |
| Alao JP et al. | The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. | 2006 | Mol. Cancer | pmid:16503970 |
| Alao JP et al. | Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. | 2006 | Mol. Cancer | pmid:16504004 |
| Kuljaca S et al. | Enhancing the anti-angiogenic action of histone deacetylase inhibitors. | 2007 | Mol. Cancer | pmid:17958916 |